Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Kerry Lynn Reynolds, M.D.

Co-Author

This page shows the publications co-authored by Kerry Reynolds and Meghan Mooradian.
Connection Strength

3.069
  1. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.245
  2. Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. Front Immunol. 2022; 13:871452.
    View in: PubMed
    Score: 0.243
  3. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.233
  4. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.230
  5. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 08; 26(8):e1427-e1433.
    View in: PubMed
    Score: 0.228
  6. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.226
  7. The Art of Oncology: COVID-19 Era. Oncologist. 2020 11; 25(11):997-1000g.
    View in: PubMed
    Score: 0.218
  8. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep. 2020 03 21; 22(4):39.
    View in: PubMed
    Score: 0.211
  9. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.206
  10. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
    View in: PubMed
    Score: 0.206
  11. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 2019 06; 48(6):1127-1132.
    View in: PubMed
    Score: 0.191
  12. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. Eur Radiol. 2021 Dec; 31(12):8868-8878.
    View in: PubMed
    Score: 0.057
  13. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann Oncol. 2021 08; 32(8):1050-1051.
    View in: PubMed
    Score: 0.057
  14. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol. 2021 02; 32(2):187-195.
    View in: PubMed
    Score: 0.056
  15. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
    View in: PubMed
    Score: 0.055
  16. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.055
  17. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol. 2020 05; 87(5):659-669.
    View in: PubMed
    Score: 0.053
  18. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700.
    View in: PubMed
    Score: 0.051
  19. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. JAMA Netw Open. 2019 09 04; 2(9):e1911952.
    View in: PubMed
    Score: 0.051
  20. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019 09 10; 93(11):e1093-e1103.
    View in: PubMed
    Score: 0.050
  21. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746.
    View in: PubMed
    Score: 0.050
  22. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999.
    View in: PubMed
    Score: 0.050
  23. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.